Glucagon Incretin-related Reporter HEK 293 Cells - Glucagon Bioassay

Cell line description

HEK-Blue™ Glucagon cells were generated by stable transfection of the human embryonic kidney HEK293 cell line with the gene encoding human glucagon receptor (GCGR). In addition, a SEAP (secreted embryonic alkaline phosphatase) reporter gene under the control of a minimal promoter fused to nine cAMP response elements (CRE) was introduced. Binding of glucagon or a synthetic hormone receptor agonist to the GCGR on the surface of HEK-Blue™ Glucagon cells triggers a signaling cascade leading to the activation of the CRE-binding Protein (CREB) pathway and the subsequent production of SEAP. This can be readily assessed in the supernatant using QUANTI‑Blue™ Solution, a SEAP detection reagent. 

HEK‑Blue™ Glucagon cells respond to glucagon and other GCGR agonists, such as Retatrutide. They do not respond to other G protein-coupled receptor (GPCR)-activating hormones or their analogs, including GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), Semaglutide, Orforglipron, or Tirzepatide. HEK-Blue™ Glucagon cells express approximately 16,000 glucagon receptors per cell, a surface receptor density consistent with physiological levels reported in the literature [1].

Glucagon background

Glucagon is a peptide hormone produced by pancreatic α cells. It acts as a key counter-regulatory hormone to insulin in maintaining glucose homeostasis [2]. During fasting or physical exertion, its primary role is to prevent hypoglycemia and to mobilize energy metabolism. It exerts its effects through the glucagon receptor (GCGR), a G protein-coupled receptor (GPCR) expressed primarily in hepatocytes. Upon GCGR binding, it stimulates hepatic glucose output between meals, reduces appetite, decreases gastrointestinal motility, and enhances lipolysis as well as hepatic fatty acid oxidation [2]. 

Although glucagon is not considered an incretin - since it is produced by pancreatic α cells rather than the gut - it belongs to the same glucagon peptide family and shares structural and signaling similarities with GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide aka gastric inhibitory polypeptide). Notably, glucagon signaling via GCGR, is engaging the canonical Gs/adenylyl cyclase/cAMP/PKA/CREB pathway, which is likewise activated by GIP and GLP-1 [3]. As a key transcription factor, CREB mediates many of the downstream effects of glucagon, including the regulation of gluconeogenesis, autophagy and cell survival, as well as lipid metabolism [3].

The discovery of the synergistic interplay between glucagon and GLP-1 has highlighted the important contribution of glucagon to lipid oxidation and energy expenditure. In combination, these hormones promote metabolic flexibility by enhancing energy mobilization while maintaining glycemic control. This complementary mechanism, integrating glucagon-induced thermogenesis and fat oxidation with GLP-1–mediated satiety and insulin secretion, represents a promising strategy for the treatment of obesity [4]. This concept has driven the development of novel multi-agonist therapies. While Tirzepatide (Mounjaro®/Zepbound®) acts as a dual GLP-1/GIP agonist, newer compounds, like Retatrutide (LY3437943), additionally target the glucagon receptor, further enhancing energy expenditure. These long-acting agents are at the forefront of a new generation of metabolic therapies, showing substantial efficacy in the management of type 2 diabetes and obesity, and are currently being investigated for broader indications including non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) [4].

1. Desbuquois B & Authier F, et al. 1989. Récepteurs du glucagon [Glucagon receptors]. Ann Endocrinol (Paris). 1989;50(5):440-6. French.
2. Zeigerer A, et al. 2021. Glucagon’s Metabolic Action in Health and Disease. Compr Physiol. 2021 Apr 1;11(2):1759-1783.
3. Müller TD et al., 2025 Glucose-dependent insulinotropic polypeptide (GIP). Mol Metab. 95:102118.
4. Gutgesell RM et al. 2024. Dual and Triple Incretin-Based Co-agonists: Novel Therapeutics for Obesity and Diabetes. Diabetes Ther. 2024 May;15(5):1069-1084.